Trial Profile
Phase I Study of Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Olvimulogene nanivacirepvec (Primary)
- Indications Breast cancer; Carcinoma; Malignant pleural effusion; Mesothelioma; Non-small cell lung cancer
- Focus Adverse reactions
- 08 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 08 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 10 Jul 2023 Results presented in Genelux Corporation media release.